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EDITORIAL

Rise of the Small Machines: Salvation

I

f you had not noticed, you are probably working harder
than ever to remain as productive as before. Given the
ongoing financial and regulatory landscapes in nephrology and medicine, in general, this scenario represents
a formula for disaster and self-implosion. More than
ever, we must acknowledge and invoke the mantra of
former Walt Disney Company cartoonist, Carl Barks:
‘‘Work smarter, not harder.’’ Thinking small, not small
thinking, portends large advances in nephrology.
Machine automation on the small scale will permit us to
do this, and technical innovation, particularly in the field
of nanotechnology, which uses ‘‘machines’’ that manipulate matter on the scale of 1 to 100 nm to perform specific
functions, is our future.
And what is a machine? Classically, it was a mechanical, thermal, or electrical device—an assemblage of typically moving parts, like an automobile, that was
unpowered or powered and that yielded a mechanical
advantage or reduced the amount of effort required to
accomplish a given task compared with the manual effort
required by the same task. An archaic definition
of a machine is a constructed thing, and this definition
and the former apply to nanomachines, which are
small machines constructed for a purpose and with
high-efficiency yields such that when in high number,
performance of dauntingly large tasks is feasible. Nanotechnology is destined to be a key driver for success in
clinical nephrology, particularly in the ESRD arena.
With this in mind, Dr. William Fissell, MD, graciously
accepted this guest editorship of Advances in Chronic Kidney Disease entitled ‘‘Nanotechnology in Kidney Disease.’’
As with computing, as mainframe computers have
been progressively shrunken into mobile devices,
advances in nephrology have proceeded with a reduction
in size. Hemodialysis machines, which once occupied
nearly the space of a small room, have been tremendously condensed, and one has been created ‘‘off-theshelf’’ for infant dialysis1 and another can now be worn
for an entire day. In the former circumstance, an English
consultant constructed a one-of-a-kind, do-it-yourself

hemodialysis machine for his infant patient.2 In the second instance, the most recent prototype of the wearable
artificial kidney by Gura and colleagues2 has been recognized by the U.S. Food and Drug Administration’s 2012
Innovation Challenge program for potential fast track
to marketing3-5 At a clearance of 40 to 50 mL/minute,
this 4.5-kg device, worn 24 hours daily, achieves
standard weekly Kt/V levels approximating 7, which is
clearly superior to any other current dialysis modality,
including short daily and nocturnal hemodialysis.
Recently, an even smaller hemodialysis device was
created that uses nanotechnology. This device, devised
by Kanno and Miki,6 extends the observations of Uesaka
of nanotechnology applied polysulfone membranes,7 and
such a device has potential applicability for implantation,
substituting for the function of the natural organs, using
convection as the principal cleansing modality. Note that
this had been intimated as a possibility as long as a decade ago.8 In the future, with increasing miniaturization,
the wearable artificial kidney has potential to become as
popular as the other home-based therapies: short, daily
dialysis and peritoneal dialysis.
Miniaturization of sensors could also have broad
application in hemodialysis. For example, if sensors
could be sterilely apposed to the blood space, the instantaneous determinations of ionized calcium and phosphate concentrations, among other analytes, during
extended periods of hemodialysis would provide safety
and benefit. Moreover, the readout of such sensors could
be used in a servo loop, providing autofeedback to the
system for adjustment of these critical analytes, thereby
preventing ionized hypocalcemia and hypophosphatemia—the most feared complication of continuous renal
replacement therapies that use regional citrate anticoagulation. An ionized calcium sensor has been developed by
Yang and colleagues, and it determines ionized calcium
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levels nearly instantaneously. With knowledge of mass
balances in an extracorporeal circuit, the placement
of this sensor would indirectly ‘‘measure’’ plasma ionized
calcium. Likewise, a separate sensor that distinguishes
citrate anion has been used to determine whether
citrate accumulation is occurring during sustained,
low-efficiency dialysis, permitting rapid, critical adjustments.9 The ex vivo modeling of a regional citrate anticoagulation sustained low-efficiency dialysis system was
aided and abetted by this sensor technology and ultimately facilitated an enhanced system design that actually does not require ionized calcium.10
Further introductions of sensor technology for glucose
and cytokine measurements in various body fluids may
provide, in the future, widespread capability for the
rapid recognition and attenuation of catastrophic clinical
consequences, such as hypoglycemia and septic shock.
Perhaps other biological sensors would be able to detect
clinically undetectable events such as when a hemodialysis or peritoneal dialysis catheter becomes encrusted with
the biofilm of microorganisms and when biofilm detachment is imminent. A quorum-sensing sensor in this circumstance might provide guidance for hemodialysis
or peritoneal catheter exchanges, removals, and the
peremptory use of anti-infectives.11 In relation to the
latter, coupled, spatial, site-specific, nanoparticle-based
pharmacotherapy could prove lifesaving. This would
be particularly efficacious for the nonwater-soluble antimicrobial agents and for situations in which supratherapeutic local drug levels would be advantageous.12
The small machines may also provide nephrologists
with water that is purer than that which we have ever
afforded our patients. We take pride in the generation
of high Kt/V values for our patients; however, the
greater the value, the greater the potential exposure
to waterborne contaminants that have slipped by our
conventional filtration systems and reverse osmosis.
Contaminated water supplies must be identified as rapidly as possible. Alternatively, eschewing conventional
water supplies would be ideal; however, using ultrapure
water is prohibitively expensive for large or small dialysis organizations. Therefore, working smarter is certainly
applicable with regard to the acquisition and distribution
of pure water. Simply making new the plumbing of an
in-center hemodialysis unit is not the answer. Biofouling
and biofilm production will simply and inevitably
recur—and within days—because of the reality that the
source of the water supply is generally extrinsic to the
hemodialysis unit.13
Nanofilters require less pressure to be effective
than conventional filters and surface contact is substantially greater. In addition, cleansing of filters via
back-flushing is easier than required of conventional
methods.14 Alumina and other nanofiber materials can
be manufactured into nanofilters and devised to remove
viruses, bacteria, arsenic, fluoride, heavy metals, and

other potentially toxic organic and inorganic colloidal
particles at rates faster than those currently attained. It
is important to note that the diameter of these carbon
nanoporous structures permits low-power flow-through
of water molecules, without fouling, but it excludes
unwanted pathogens and contaminants.15 Using and
deploying nanotechnology in distressed areas bereft of
water or without access to potable water sources is potentially lifesaving. In areas where emergent renal replacement therapy becomes critical, as may transpire after
natural disasters such earthquakes and tsunamis, nanotechnology would be indispensable.
Nanotechnology-based gene therapy affords promise
for systemic disorders that cause CKD. Dr. Conforti and
her team were recently funded by the National Institutes
of Health to investigate how nanoscale therapy can alter
immune function in the hopes of abrogating the effects of
a pathobiological, hyperimmune system as is the case
in systemic lupus erythematosus.16 By gene-targeting
a voltage-gated potassium ion channel (Kv) on T cells
with nanoliposomes, calcium-based signaling is interdicted, thereby limiting the undesirable amplification of
the immune response. This novel and biologically plausible approach could be templated to other autoimmune
disorders such as the antineutrophil cytoplasmic
antibody-associated vasculitides, among others. Customizable gene-targeting looms within the realm of possibility now that the human genome has been mapped and
a multitude of disease-inducing antigens have been, in
parallel, delineated.
The aforementioned represents but a trifling of the
potential roles that today’s and tomorrow’s nanoscale
machines may fulfill. Thinking smaller may yield large
advantages in productivity and cost savings. As always,
these advantages are contingent upon discovery, development, and implementation. If appropriate resources
are allocated toward the development of nanotechnology,
then possibility becomes probability. The rise of the small
machines will hopefully become inevitable, and with
them, some salvation . for us and our patients.
Jerry Yee, MD
Editor-in-Chief
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